Journal: Drug Delivery

Article Title: Spray-dried nanocrystal-loaded polymer microparticles for long-term release local therapies: an opportunity for poorly soluble drugs

doi: 10.1080/10717544.2023.2284683

Figure Lengend Snippet: Spray-drying set-up parameters.

Article Snippet: The investigational active pharmaceutical ingredient (API) GLPG0555 (MW: 410.43) was provided by Galapagos NV (Mechelen, Belgium).

Techniques: Solvent, Polymer, Concentration Assay

Journal: Drug Delivery

Article Title: Spray-dried nanocrystal-loaded polymer microparticles for long-term release local therapies: an opportunity for poorly soluble drugs

doi: 10.1080/10717544.2023.2284683

Figure Lengend Snippet: Complete characterization for the two selected GLPG0555 NCs (TPGS API/s ratio 1/0.1 and P407 API/s ratio 1/0.05 formulation conditions are shown in red and green, respectively). (A) Dv50 and Dv90 PSD values of fresh formulations measured by laser diffraction. (B) Particle population distribution by intensity representative peak curves of fresh formulations measured by DLS. (C) Representative zeta potential distribution curves of fresh formulations. (D) SEM representative micrographs of the initial GLPG0555, washed TPGS-stabilized NCs (E), and P407-stabilized NCs (F). Magnification is 10,000x. (G) Dv50 and Dv90 PSD values were measured by laser diffraction of FD NCs after resuspension in Milli-Q water. (H) PSD representative graphs by volume density obtained by laser diffraction of FD NCs after resuspension in Milli-Q water. (I) Total GLPG0555 recoveries after wet milling, sample harvesting, and freeze-drying. (J) Total GLPG0555 content of the NCs quantified by UHPLC. (K) Representative thermograms of the initial GLPG0555 and the NCs measured by DSC. Fusion transition events occurred around 220–230 °C. (L) Dissolution profile of GLPG0555 in both PBS (dotted lines) and in the ‘MPs release study’ medium (continuous lines). GLPG0555 was quantified by UHPLC. All results are represented by the mean ± sd ( n ≥ 3, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001); ns means non-significant.

Article Snippet: The investigational active pharmaceutical ingredient (API) GLPG0555 (MW: 410.43) was provided by Galapagos NV (Mechelen, Belgium).

Techniques: Formulation, Zeta Potential Analyzer, Wet-Milling, Dissolution

Journal: Drug Delivery

Article Title: Spray-dried nanocrystal-loaded polymer microparticles for long-term release local therapies: an opportunity for poorly soluble drugs

doi: 10.1080/10717544.2023.2284683

Figure Lengend Snippet: Interaction of the FD TPGS (API/s ratio 1/0.1) and P407 (API/s ratio 1/0.05) GLPG0555 NCs, in red and green, respectively, with the SP feed solution. (A) Normalized enthalpies of fusion (ΔH) of the NCs were analyzed by DSC. Polymer reference used was PLGA 753H (concentration 7.5% w/v) and TDL for NCs was 25% w/w. Results are the mean ± s.d. ( n = 3). (B) PSD was analyzed by laser diffraction after resuspension of the FD NCs formulations in two different ACE mixtures. Resuspension of NCs in Milli-Q water was used as a reference control. For PSD only D[3;2] (µm) values are shown. Results are the mean ± s.e.m. ( n = 3).

Article Snippet: The investigational active pharmaceutical ingredient (API) GLPG0555 (MW: 410.43) was provided by Galapagos NV (Mechelen, Belgium).

Techniques: Polymer, Concentration Assay, Control

Journal: Drug Delivery

Article Title: Spray-dried nanocrystal-loaded polymer microparticles for long-term release local therapies: an opportunity for poorly soluble drugs

doi: 10.1080/10717544.2023.2284683

Figure Lengend Snippet: (A) PSD representative graphs of MPs by volume density obtained by laser diffraction. SEM representative micrographs of (B) blank 753H MPs, (C) TPGS NCs-753H MPs, (D) P407 NCs-753H MPs, and (E) TPGS NCs-753H MP cross section. Magnifications are 4500x and 9000x for the cross-section MP. (F) Representative thermograms of the TPGS and P407 NCs loaded in the 753H MPS analyzed by DSC. Fusion transition events occurred around 200–230 °C. (G) Efficacies of encapsulation (EE), expressed as a percentage. Values are the mean ± s.d. ( n = 3). (H) Yields expressed as a percentage (100% is the initial mass weighted). n = 1. (I) PSD measured by laser diffraction after MPs resuspension. Only Dv50 and Dv90 (dotted) values are shown, n = 1. For F–H, three polymers (653H, 753H, and 203H) and two GLPG0555 NCs (TPGS API/s ratio 1/0.1, in red and P407 API/s ratio 1/0.05, in green) are shown.

Article Snippet: The investigational active pharmaceutical ingredient (API) GLPG0555 (MW: 410.43) was provided by Galapagos NV (Mechelen, Belgium).

Techniques: Encapsulation

Journal: Drug Delivery

Article Title: Spray-dried nanocrystal-loaded polymer microparticles for long-term release local therapies: an opportunity for poorly soluble drugs

doi: 10.1080/10717544.2023.2284683

Figure Lengend Snippet: Optimization of SP 753H polymer MPs loaded with TPGS (API/s ratio 1/0.1) GLPG0555 NCs: polymer concentration (% w/v) vs. TDL (% w/w). (A) SEM representative micrographs. Magnification is 4500x. (B) Efficacies of encapsulation (EE) expressed as a percentage. Data is the mean ± s.d. ( n = 3). (C) Yields vs. dv90. Yields are expressed as a percentage (100% is the initial mass weighted). Dv90 values are measured by laser diffraction after MPs resuspension. (D) Cumulative drug release profiles (%) over four months. Data is the mean ± s.d. ( n = 3). (E) Summary of fit plot (partial least squares regression model) for seven responses. Only R2 and Q2 values are shown. (F) Sweet spot plot. Met criteria response value limits were: yield > 30, Dv90 < 60 µm, burst release < 20%, 28 d release 10–50%, 56 d release 35–70%, 84 d release 50–90% and 112 d release > 80%. Data was plotted with MODDE 12.1. (Sartorius, Göttingen, Germany), using a ‘full factorial 2 levels’ orthogonal (balanced) design with all combinations of the factor levels. Main effects and all interactions are clear of each other (not confounded). n ° experiments = 7 and n = 1.

Article Snippet: The investigational active pharmaceutical ingredient (API) GLPG0555 (MW: 410.43) was provided by Galapagos NV (Mechelen, Belgium).

Techniques: Polymer, Concentration Assay, Encapsulation

Journal: Drug Delivery

Article Title: Spray-dried nanocrystal-loaded polymer microparticles for long-term release local therapies: an opportunity for poorly soluble drugs

doi: 10.1080/10717544.2023.2284683

Figure Lengend Snippet: GLPG0555 cumulative release in percentage vs. time for seven MPs formulations containing different polymers. Data is the mean ± s.d. ( n = 3). The resulting curves were fitted using different models: zero and first order, Higuchi, Hixson, and Korsmeyer–Peppas (K.P). Best model fits calculated according to the higher R 2 values are shown.

Article Snippet: The investigational active pharmaceutical ingredient (API) GLPG0555 (MW: 410.43) was provided by Galapagos NV (Mechelen, Belgium).

Techniques:

Journal: Frontiers in Veterinary Science

Article Title: Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors

doi: 10.3389/fvets.2022.888483

Figure Lengend Snippet: Time-course of sorafenib serum concentrations in tumor-bearing dogs. Mean and average sorafenib serum concentration – time profiles for four patients treated with oral sorafenib at 3 mg/kg.

Article Snippet: Sorafenib Tosylate bulk active pharmaceutical ingredient (API) was manufactured at a cGMP compliant facility and supplied by Tecoland Pharmaceuticals (Irvine, CA, USA).

Techniques: Concentration Assay